Premenstrual Syndrome (Investigational)
Investigational adjunct for moderate PMS refractory to conventional therapy; small case series only; SSRI and combined hormonal contraception remain primary.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for premenstrual syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only as an adjunct to standard pharmacotherapy.
- Какие доказательства существуют?
- Tier C (investigational). Only small uncontrolled case series describe reductions in PMS symptom scores after sessions in the luteal phase. There are no controlled trials. Per ACOG 2018 guidance, PMS (and PMDD) is managed with lifestyle modification, SSRIs (continuous or luteal-phase dosing), combined hormonal contraception, and selected nutraceuticals (calcium, vitamin B6). Diagnosis requires confirmation by prospective symptom diary over at least 2 cycles. Mechanism is plausible only for somatic symptoms (mastalgia, bloating, headache); affective symptoms are less likely to respond to peripheral therapy.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment, possibly additive to menstrual blood loss if cycle timing overlaps
- Bruising and tenderness over the lower abdomen or sacral area for 5 to 10 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Symptom worsening through pain at bite sites during the already symptomatic luteal phase
- Delay of SSRI, combined hormonal contraception, or lifestyle interventions, all of which have RCT evidence
- Missed diagnosis of PMDD requiring psychiatric stabilization
- Risk for venous thromboembolism if combined hormonal contraception is concurrent
- Кому не следует это рассматривать
- Pregnant or breastfeeding patients
- Patients with heavy menstrual bleeding (additive blood loss risk)
- Patients on combined hormonal contraception with VTE risk factors
- Patients with PMDD requiring psychiatric stabilization
- Patients without prospective symptom diary confirming PMS diagnosis
- Patients on anticoagulants or with severe anemia
- О чём спросить врача
- Has my PMS diagnosis been confirmed by prospective symptom diary over at least 2 cycles?
- Could I have PMDD or a comorbid mood disorder that needs psychiatric care?
- Have I trialed SSRIs (continuous or luteal-phase) or combined hormonal contraception?
- Have I trialed lifestyle modifications: exercise, caffeine reduction, calcium, vitamin B6?
- Where exactly will the leech be placed, and how does timing intersect with my cycle?
- What is the realistic expected benefit for somatic versus affective symptoms?
- Когда срочно обратиться за медицинской помощью
- Suicidal thoughts, severe depression, or psychiatric crisis (urgent mental-health care)
- Heavy menstrual bleeding through more than one pad per hour
- Dizziness, lightheadedness, or syncope
- Sudden severe pelvic or abdominal pain
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, pus, or red streaks at any bite site
Что это НЕ означает
- It does not replace SSRIs or combined hormonal contraception, which have RCT support.
- It is not an appropriate primary therapy for PMDD, which often requires SSRI and psychiatric care.
- It does not address affective symptoms (depression, irritability) reliably; mechanism is mostly somatic.
- Only small uncontrolled case series exist; benefit beyond placebo or concurrent therapy is uncertain.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- gynecologic
- ICD-10
- N94.3
- Safety tier
- medium
Evidence Summary
Premenstrual syndrome (and PMDD) is managed per ACOG 2018 guidance with lifestyle modification, SSRIs (continuous or luteal-phase dosing), combined hormonal contraception, and selected nutraceuticals (calcium, vitamin B6). No controlled clinical trial of leech therapy for premenstrual syndrome has been published; use is investigational and mechanistic only, and the honest evidence grade is D. A proposed antiinflammatory-peptide effect on prostaglandin-mediated symptoms is theoretical, plausible at most for somatic symptoms (mastalgia, bloating, headache); affective symptoms are unlikely to respond to peripheral therapy.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U et al. (2009)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Pregnancy or breastfeeding
- Heavy menstrual bleeding (additive blood loss)
- Combined hormonal contraception with VTE risk factors
- PMDD requiring psychiatric stabilization
Related Conditions
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.